AveragePenny
3 weeks ago
$GELS $HYEX Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand
https://www.globenewswire.com/news-release/2024/12/02/2989805/0/en/Gelteq-Announces-Largest-U-S-Customer-Increases-Initial-Order-by-50-to-Meet-Growing-Market-Demand.html
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (βGelteqβ or the βCompanyβ), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces its largest U.S. customer, Healthy Extracts (OTCQB:HYEX), has increased its initial purchase order of Gelteq collagen and Mynus sugar blocker gels by 50%, citing high demand and popularity of the products. Healthy Extractsβ platform acquires, develops, patents, markets, and distributes plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar nutraceuticals market.
This growing partnership supports Gelteqβs strategic push into the U.S. market following the recent hiring of Adam Bendell as the Companyβs U.S. President and the establishment of a U.S.-based office. Production of Healthy Extractsβ order is underway, with shipment expected in January 2025.
βGelteq is dedicated to delivering products offering an improved delivery platform to those who may struggle to swallow or digest traditional nutraceutical products, which we anticipate will result in improved commercial success,β Gelteq Co-Founder and CEO Nathan Givoni said. βOur partnership with Healthy Extracts is a perfect example of how our formulations can create a revolutionary and convenient way for consumers to ingest the product with the added benefits of easier digestion and better absorption. We believe the increase in demand is a testament to our innovative products and a positive step forward in our commitment to building long-term shareholder value.β
βGelteqβs advanced technology offers a cutting-edge delivery system that empowers us to expand existing sales channels and capitalize on new market opportunities, all while delivering a more satisfying and impactful experience for consumers. This partnership is poised to drive higher margins, accelerate revenue growth, and strengthen our leadership in the rapidly expanding U.S. health and wellness market. We are confident that Gelteq's collaboration will be a pivotal factor in driving the sustained growth and success of our business,β said Duke Pitts, Healthy Extracts President.
Gelteq and the Healthy Extracts team will continue to expand the range of their partnership and expect to announce new products in early 2025.
AveragePenny
1 month ago
$HYEX Healthy Extracts Reports Record Q3 2024; Issues Guidance for 20%+ Growth and Positive Cash Flow for Full Year 2024
https://www.accesswire.com/941417/healthy-extracts-reports-record-q3-2024-issues-guidance-for-20-growth-and-positive-cash-flow-for-full-year-2024
Net revenue up 21% year-over-year to record third-quarter high.
Achieved fourth consecutive positive cash flow quarter while still investing in future growth.
Growth in subscription-based sales generating an expanding recurring revenue stream.
Record increase in subscriptions driving greater customer lifetime value (CLV).
Outlook remains on track for more than 20% revenue growth in 2024, exceeding $3 million, and generate cash flow positive for the year.
LAS VEGAS, NV / ACCESSWIRE / November 12, 2024 / Healthy Extracts Inc. (OTCQB:HYEX), a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar nutraceuticals market, reported results for the three and nine months ended September 30, 2024. All comparisons are to the year-ago period unless otherwise noted.
Q3 2024 Financial Highlights
Net revenue increased 21% to $745,000, a record for a third quarter, which was driven primarily by consumer sales growth and increased subscription-based revenue.
Gross profit increased 22% to $602,000 with gross margin up 50 basis points to 80.9% due to improved manufacturing efficiency and product mix.
Operating expenses decreased 31% to $517,000.
Reduced outstanding debt by $97,000, which brought the total debt reduction over the past two quarters to $205,000 and enabling additional capital to be applied to growth initiatives.
Net income totaled $355,000 or $0.12 per basic and diluted share, improving from a loss of $248,000 in the same year-ago period. The increase was primarily due to a change in fair value on derivative expense. Excluding expenses related to potential acquisitions and equity offerings, regulatory compliance, stock-based compensation, change in fair value of derivative expense and interest, net income in the third quarter of 2024 totaled $117,000 or $0.04 per basic and diluted share.
Amazon "Subscribe & Save" customers at September 30, 2024 increased 63% year-over-year to a record number of subscribers. Direct-to-consumer subscription customers (excluding Amazon) at September 30, 2024 increased 97% year-over-year. Subscription growth helps reduce customer acquisition costs, increases traction, and provides greater visibility into future revenue.
Management Commentary
"In Q3, we achieved another quarter of record-breaking revenue along with additional margin improvements and debt reduction," commented Healthy Extracts president, Duke Pitts. "This strong performance was driven by the sale of industry-leading products through our well-developed and diverse marketing channels-especially direct-to-consumer.
"The results also reflect how we achieved record-breaking Amazon sales in July and August, with this resulting from effectively targeted sales and marketing efforts for Prime Day, as well as record demand for our Amazon βSubscribe & Save' offerings.
"We also maintained a top three position among more than 100 competitors in Amazon's popular Citrus Bergamot category. We're looking forward to strong Black Friday and Cyber Monday events coming up later this month that we expect will take our Amazon sales to the next level.
"Given the tremendous success of our Amazon βSubscribe & Save' program, in July we introduced a 20% discount on monthly subscriptions on our direct-to-consumer eCommerce website, replacing our traditional Buy-2-Get-1 offers. This new offering has been well received, resulting in notable growth in subscription sign-ups.
"We see this new program helping to boost our sales and margins, as well as enable greater customer long-term retention rates. We estimate our subscription-based revenue is quickly approaching nearly a third of our overall revenue run-rate, with this supporting a significant increase in overall customer lifetime value or CLV.
"Now with our strongest fundamentals to date, including a streamlined capitalization structure, manageable debt levels, and four consecutive quarters of positive cash flow, our company is positioned exceptionally well.
"Despite navigating limited working capital due to challenging financial markets, we have maintained a consistent growth trajectory with a compound annual growth rate of approximately 25% over the last three years. Based on typical industry valuation multiples applied just to our Customer Lifetime Value (CLV), we believe our current market valuation is highly undervalued.
"For the rest of the year and into the next, we expect to continue to strengthen our top-line growth, profitability, and market share, especially as our addressable markets continue to expand. Our consistent growth momentum with our retail customers positions us well for the successful launch of new products that we're planning to roll out in the current fourth quarter. We are also in the best-ever position for making strategic, accretive acquisitions that would further accelerate our growth.
"The launch of these new products will benefit from the broad market channels we have strategically built and invested in over recent years. We believe these investments have proven to be the most effective way to create significant shareholder value. The continued pursuit of this strategy remains our top priority. Given our momentum coming into the fourth quarter, we expect to report record revenue and positive cash flow for the year, with this setting the stage for accelerated growth in 2025."
Financial Outlook
For the remainder of 2024, the company expects to remain on track for another year of record revenue at more than $3.0 million, representing a 20%+ year-over-year gain, and generate positive cash-flow for the year. New product introductions are expected to continue laying the way for stronger growth and greater profitability excluding non-cash expenses.
Product Outlook
Healthy Extracts' top brand ambassador and renowned fitness expert, Whitney Johns, is preparing to launch WHITNEY JOHNS™ NUTRITION on-the-go gel packs for COLLAGEN (anti-aging) in the first quarter of 2025. These products will be based on Healthy Extracts' exclusive oral delivery system and proprietary formulations.
The company is also planning to launch in the first quarter of 2025 its new BergaMet MYNUS sugar blocker, which is specially formulated to reduce up to 42% of the sugar impact from meals. The MYNUS on-the-go gel-packs will be made available under the company's exclusive U.S. and Canadian licensing and manufacturing agreement with Gelteq.
Q3 2024 Financial Summary
Net revenue in the third quarter of 2024 increased 21% to $745,000 from $614,000 in the same year-ago quarter, primarily due to consumer sales growth and increased subscription-based revenue.
Gross profit totaled $602,000 or 80.9% of net revenue as compared to $493,000 or 80.4% of net revenue in the same year-ago quarter. The 50 basis points increase in gross margin was the result of manufacturing efficiency and more favorable product mix.
Operating expenses decreased 31% to $517,000 as compared to $754,000 in the same year-ago quarter. The decrease in operating expenses was primarily due to one-time expenses in the year-ago quarter related to the company's planned uplist to Nasdaq and issuance of options and warrants that did not reoccur in the third quarter of 2024, and to a lesser extent the reduction in general operating expense in the third quarter of 2024.
Net income totaled $354,000 or $0.12 per basic and diluted share, as compared to a net loss of $248,000 or $(0.09) per basic and diluted share in the same year-ago period.
Excluding expenses related to planned acquisitions and public offerings, regulatory compliance, stock-based compensation, the change in fair value of derivative expense and interest expense, net income in the third quarter of 2024 totaled $117,000 or $0.04 per basic and diluted share versus net income of $33,000 or $0.01 per basic and diluted share.
First Nine Months of 2024 Financial Summary
Net revenue in the first nine months of 2024 increased 29% to a record $2.3 million compared to $1.8 million in the same year-ago period, primarily due to product line and distribution channel expansion.
Gross profit totaled $1.5 million or 63.9% of net revenue as compared to $1.1 million or 58.1% of net revenue in the same year-ago period. The increase in gross margin was a result of product mix sold as well as decreases in manufacturing and freight costs.
Operating expenses decreased 50% to $1.5 million compared to $3.0 million in the same year-ago period. The decrease in operating expenses was primarily due to one-time expenses in the same year-ago period related to the company's planned uplist to a Nasdaq and the issuance of options and warrants that did not reoccur in the 2024, and to a lesser extent the reduction in general operating expense in 2024.
Net loss totaled $394,000 or $(0.13) per basic and diluted share, compared to a loss of $2.1 million or $(0.72) per basic and diluted share in the same year-ago period. The improvement in net loss was primarily due to the same factors that drove improvement in the third quarter of 2024.
Excluding expenses related to the potential acquisitions and a public offering, regulatory compliance, stock compensation, change in fair value on derivative and interest expense, net income totaled $139,000 or $0.05 per basic and diluted share versus a net loss of $480,000 or $(0.16) per basic and diluted share in the same year-ago period.
AveragePenny
2 months ago
$HYEX Healthy Extracts Expects to Report Record Third Quarter 2024, with Net Revenue Up More than 20%
https://www.accesswire.com/932595/healthy-extracts-expects-to-report-record-third-quarter-2024-with-net-revenue-up-more-than-20
Strong Growth in Subscription-Based Recurring Revenue Continues for Healthy Extracts as Category Top Three Amazon Seller
LAS VEGAS, NV / ACCESSWIRE / October 17, 2024 / Healthy Extracts Inc. (OTCQB:HYEX), a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar nutraceuticals market, reported preliminary record results for the third quarter ended September 30, 2024.
Net revenue is expected to exceed $740,000, a record for a third quarter, up more than 20% compared to the same year-ago quarter.
Gross margin for the quarter is expected to exceed 80%, driving positive operating cash flow and net profitability.
"In Q3, we achieved another quarter of record-breaking revenue, continued margin improvements, and further debt reduction, with this driven by robust performance in our direct-to-consumer channels," stated Healthy Extracts president, Duke Pitts. "This consistent growth momentum with our key retail customers positions us for the successful launch of new products we are planning to introduce in the current quarter."
The company generated record sales on Amazon in July, primarily as a result of its focused sales and marketing efforts for Prime Day and increased demand for its "Subscribe & Save" offers. During the quarter, the company continued to rank as a top three seller of Citrus Bergamot on Amazon among more than 100 competitors.
The company's products feature the only heart health supplement distributed in North America containing Citrus Bergamot SuperFruit™, which has the highest known concentration of polyphenols and flavonoids.
Given the success with Amazon's "Subscribe and Save," in July Healthy Extracts replaced its traditional buy-2-get-1 offers on its eCommerce website with a 20% discount for subscribing to monthly shipments.
"We expect this move to increase sales and margins, as well as the lifetime value of our customers due to improved customer retention," noted Pitts. "In fact, the new offer has been well received, generating a significant increase in overall subscriber growth during the first several weeks."
Looking ahead, the company anticipates strengthening performance in top-line growth, profitability, and market share expansion as its addressable markets continue to grow. This positive outlook is largely due to the anticipated launch of new products that will benefit from the broad market channels the company has strategically developed and invested in over the past several years.
According to Pitts, "These investments have proven to be the most effective way to create significant shareholder value-and this will continue to be our top priority."
The preliminary unaudited results presented in this press release are estimates only and are subject to revision until the company officially reports its quarterly results in mid-November.
makinezmoney
3 years ago
$HYEX: Great Quarterly Earnings report.... Revs up 187%
Very nice
Now at 0.055
Healthy Extracts Expects Q1 2022 Net Revenue up 187% to Record $489,000, Driving First Profitable Quarter
April 12, 2022 08:31 ET | Source: Healthy Extracts Inc.
...
LAS VEGAS, April 12, 2022 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, reported preliminary unaudited results for the first quarter ended March 31, 2022.
Net revenue for the first quarter is expected to total more than $489,000, up 187% over the same year-ago quarter, and keeps full year outlook on track for revenue to double to more than $3 million.
βOur record top-line for a first quarter resulted primarily from expansion of direct-to-consumer channels, including a four-fold increase in recurring revenue from product subscriptions,β stated Duke Pitts, president of Healthy Extracts. βWe also expect this strong performance to drive our first-ever positive net income quarter.β
Over the past year, the company established a solid foundation for addressing the fast-growing brain and heart health supplement market, including key acquisitions and successful clinical studies that support its productsβ health benefit claims.
βWe believe the progress we have made, particularly with expanding our sales channels and portfolio of clinically proven natural products, keeps us on course for our earlier guided 100% sales growth in 2022,β added Duke. βTogether with our continued focus on building our recurring revenue stream from subscriptions, we anticipate a continued strengthening of our shareholder value throughout the year.β
The preliminary unaudited results are estimates only and are subject to revision until the company reports its financial results for the first quarter ended March 31, 2022, which it expects to report in May.
About Healthy Extracts βLive Life Young Againβ
Healthy Extracts Inc. is a platform for developing or acquiring science-forward, clinically proven, plant-based proprietary products in select high-growth categories within the multibillion-dollar nutraceuticals market.
The companyβs subsidiaries, BergametNAβ’ and Ultimate Brain Nutrientsβ’ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement containing Citrus Bergamot SuperFruitβ’. This superfruit is known to have the highest quality and concentration of polyphenols and flavonoids, and with healthy heart benefits backed by more than 17 clinical studies.
UBN KETONOMICS® proprietary formulations have been clinically shown to improve brain health, including memory, cognition, focus and neuro-energy. UBN is pursuing intellectual property license opportunities for monetizing its IP portfolio of multiple issued and pending patents.
For more information visit: healthyextractsinc.com, bergametna.com or tryubn.com.
Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on April 1, 2022, and future periodic reports filed with the SEC. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.
The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.
Food and Drug Administration Disclosure
The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctorβs advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.
BergametNAβ’, Ultimate Brain Nutrientsβ’, UBNβ’, Citrus Bergamot SuperFruitβ’ and F4T® are registered trademarks of Healthy Extracts Inc.β’
Healthy Extracts Company Contact
Duke Pitts, President
Healthy Extracts Inc.
Tel (720) 463-1004
Email contact
Investor Contact:
Ronald Both or Justin Lumley
CMA
Tel (949) 432-7566
Email contact
Media Contact:
Tim Randall
CMA
Tel (949) 432-7572
Email contact
GO $HYEX